Physician profile
Naureen Alim
NPI 1134374184
$396,673.30
in general payments reported to CMS, 2019-2025
39 companies · $114K in 2025
The $114K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $773 · 2021: $14K · 2022: $57K · 2023: $99K · 2024: $111K · 2025: $114K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $256K · Travel and Lodging: $45K · Consulting Fee: $13K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $255,861.00 |
| Travel and Lodging | $44,835.03 |
| Consulting Fee | $12,830.00 |
| Food and Beverage | $10,361.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268,182.50 | 2019-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $53,648.43 | 2021-2025 | Saphnelo, Tezspire |
| Amgen INC. | $31,311.32 | 2019-2025 | Otezla, Otezla, Evenity |
| Genzyme Corporation | $27,694.81 | 2019-2025 | |
| Glaxosmithkline, LLC. | $10,307.54 | 2019-2025 | Benlysta |
| US Oncology Corporate, INC. | $1,123.00 | 2023 | |
| Ucb, INC. | $542.34 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $420.12 | 2019-2023 | Taltz |
| Janssen Biotech, INC. | $381.00 | 2019-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $366.29 | 2021-2024 | Lupkynis |
| Pfizer INC. | $338.38 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $293.11 | 2020-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $250.93 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $201.74 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $193.24 | 2019-2025 | Orencia |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naureen Alim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.